The efficacy of 2′,2′-difluorodeoxycytidine (gemcitabine) combined with interferon in human renal cell carcinoma cell lines

International Journal of Oncology

Volumn 12, Issue 6, 1998, Pages 1361-1366

  Rohde, Detlef ^a   Hayn, Heike Karina ^a   Blatter, Johannes ^b   Jakse, Gerhard ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b LILLY DEUTSCHLAND GMBH   (Germany)

Author keywords

2 ,2 difluorodeoxycytidine; Interferon; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; GAMMA INTERFERON; GEMCITABINE; VINBLASTINE;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; COLORIMETRY; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFICACY; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; LONG TERM EXPOSURE; PRIORITY JOURNAL;

EID: 0031814809     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.12.6.1361     Document Type: Article

References (24)

1. Atzpodien J, Kirchner H, Haenninen EL, Deckert M, Fenner M and Poliwoda H: Interleukin-2 in combination with interferon-α and 5-fluorouracil for metastatic renal cell carcinoma. Eur J Cancer 29 A (Suppl 5): 6-8, 1993.
2. Plunkett W, Huang P, Searcy CE and Gandhi V: Gemcitabine: pharmacology and mechanisms of action. Semin Oncol 23 (Suppl 10): 3-15, 1996.
3. De Mulder PHM, Weissbach L, Jakse G, Osieka R, Blatter J and Ermisch S: Gemcitabine: a phase II study in patients with advanced renal cancer. Cancer Chemother Pharmacol 37: 491-495, 1996.
4. Mertens WC, Eisenhauer EA, Moore M, Venner P, Stewart D, Muldal A and Wong D: Gemcitabine in advanced renal cell carcinoma. A phase II study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 4: 331-332, 1993.
5. Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H and Parks WP: In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst 51: 1417-1423, 1973.
6. Naito S, von Eschenbach ACC, Giavazzi R and Fidler IJ: Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice. Cancer Res 46: 4109-4115, 1986.
7. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S and Boyd MR: New colorimetric assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112, 1990.
8. Monks A, Scudiero D, Skehan P, Shoemaker R, Paul K, Vistica P, Hose C, Langley J, Cronise P, Vaigro-Wolff A, Gray-Goodrich M, Campbell H, Mayo J and Boyd M: Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 83: 757-766, 1991.
9. Fossa SD, Marinelli G, Otto U, Schneider G, Wander H, Oberling F, Bauer HW, Achtnicht U and Holdener EE: Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: results or a European multicenter phase III study. Ann Oncol 3: 301-305, 1992.
10. Gohji K, Maeda S, Sugiyama T, Shigami J and Kamidono S: Enhanced inhibition of anticancer drugs by human recombinant gamma-interferon for human renal cell carcinoma in vitro. J Urol 137: 539-543, 1987.
11. Ohmura K and Tsukamoto T: Antiproliferative effect of interferon-alpha on human renal cell carcinoma in clonogenic assay - single and combination effect with cancer chemotherapeutic agent. Hinyokika Kiyo 35: 737-747, 1989.
12. Homma A and Aso Y: Effect of alpha-interferon alone and combined with other antincoplastic agents on renal cell carcinoma determined by the tetrazolium microculture assay. Eur Urol 25: 164-170, 1994.
13. Jezersek B, Novakovic S, Sersa G, Auersperg M and Fleischmann WR: Interactions of interferons and vinblastine on experimental tumor model melanoma B-16 in vitro. Anticancer Drugs 5: 53-56, 1994.
14. Wadler S and Schwartz EL: Anti-neoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res 50: 3473-3486, 1990.
15. Ferrajoli A, Liberati AM, Caricchi P, Donti E, Morra E, Lazzarino M, Bernasconi P and Saglio G: Interferon-alpha plus low-dose cytosine arabinoside in advanced phase chronic myelogenous leukaemia patients. Eur J Haematol 55: 184-188, 1995.
16. Arthur CK and Ma DD: Combined interferon alfa-2a and cytosine arabinoside as first-line treatment for chronic myeloid leukemia. Acta Haematol 89 (Suppl 1): 15-21, 1993.
17. Kantarjian HM, Keating MJ, Estey EH, O'Brien S, Pierce S, Beran M, Koller C, Feldman E and Talpaz M: Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine. J Clin Oncol 10: 772-778, 1992.
18. Palmieri G, Morabito A, Rea A, Caraglia M, Tagliaferri P and Bianco AR: Cytosine arabinoside (Ara-C) plus alpha-interferon (alpha IFN) determine prolonged complete remissions in patients with aggressive non-Hodgkin's lymphoma partially responsive to first-line doxorubicin-containing regimens. Br J Haematol 88: 421-423, 1994.
19. Ruiz van Haperen VW, Veerman G, Boven E, Noordhuis P, Vermorken JB and Peters GJ: Schedule dependence of sensitivity to 2′,2′-difluorodeoxycytidine (gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours. Biochem Pharmacol 48: 1327-1339, 1994.
20. Ruiz van Haperen VW, Verman G, Erikson S, Stegmann APA and Peters GJ: Induction of resistance to 2′,2′-difluorodeoxycytidine in the human ovarian cancer cell line A2780. Semin Oncol 22 (Suppl 11): 35-41, 1995.
21. Huang P and Plunkett W: Induction of apoptosis by gemcitabine. Semin Oncol 22 (Suppl 11): 19-25, 1995.
22. Bouffard DY and Momparler RL: Comparison of the induction of apoptosis in human leukemic cell lines by 2′,2′-difluorodeoxycytidine (gemcitabine) and cytosine arabinoside. Leuk Res 19: 849-856, 1995.
23. Rodriguez-Villanueva J and McDonnell TJ: Induction of apoptotic cell death in non-molanoma skin cancer by interferon-alpha. Int J Cancer 61: 110-114, 1995.
24. Osborne BA and Schwartz LM: Cell death suffers a TKO. Bioessays 17: 557-559, 1995.